NEPHROPLUS Share Price Target 2035

CAGR-based price projection for Nephrocare Health Services Limited (NEPHROPLUS) targeting 2035, derived from official NSE exchange closing prices.

Bear Case (6.3% CAGR)
Rs 1,127
2035 Target
Base Case (15.8% CAGR)
Rs 2,434
2035 Target
Bull Case (44.4% CAGR)
Rs 17,704
2035 Target

Current Market Snapshot

CMP: Rs 648.95
52W High: Rs 765.35
52W Low: Rs 529.25
1Y CAGR: 34.1%
3Y CAGR: 15.8%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 690 Rs 752 Rs 937
2028 Rs 734 Rs 871 Rs 1,353
2029 Rs 780 Rs 1,008 Rs 1,954
2030 Rs 829 Rs 1,168 Rs 2,821
2031 Rs 882 Rs 1,353 Rs 4,073
2032 Rs 938 Rs 1,567 Rs 5,881
2033 Rs 997 Rs 1,814 Rs 8,492
2034 Rs 1,060 Rs 2,102 Rs 12,261
2035 Rs 1,127 Rs 2,434 Rs 17,704

Other NEPHROPLUS Price Targets

2025 2026 2027 2028 2030 2040 2050

Frequently Asked Questions

What is the NEPHROPLUS share price target for 2035?

Based on historical growth analysis, the NEPHROPLUS share price target for 2035 ranges from Rs 1,127 (conservative) to Rs 2,434 (base case) to Rs 17,704 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of NEPHROPLUS?

The current market price of NEPHROPLUS (Nephrocare Health Services Limited) is Rs 648.95. The 52-week high is Rs 765.35 and 52-week low is Rs 529.25.

Is NEPHROPLUS a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for NEPHROPLUS price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 6.3% CAGR), Base (15.8% CAGR), and Bull (optimistic at 44.4% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.